This announcement is a separate document:
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- Welcome RewardsOpen an account and get up to HKD1800!
- Enjoy limited-time 5%+5% returns on Cash PlusInvest any amount and enjoy a 5% average return on Cash Plus + 5% welcome reward
- Join Futubull Membership ProgramUnlock 11 Premier Benefits
- Referral PromotionBring a friend and collect up to HK$600 in rewards
- Learn PremiumAnalyst 1V1 online teaching
- Stock TransferSwitch to Futu and get up to HK$7,000 in rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
Strandline Resources Ltd: Quarterly Activities and Cashflow Report
Jan 27, 2022 05:15
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
23:00
In November, the manufacturing index in the usa rose to 48.4, higher than the estimated 47.5.
22:59
The far-right political party "National Rally" (RN) stated on social media that they would support a motion of no confidence against the government.
22:57
Medical device manufacturer Novocure Ltd. (NVCR.US) initially rose by about 42%, but the increase has narrowed to 26.8%, marking the largest intraday increase since January 2023. Latest research results indicate that the company's cancer therapy Tumor Treating Fields for pancreatic cancer has achieved its primary endpoint.
NVCR+37.23%